Consolidated Balance Sheet

Oncolys BioPharma Inc. - Filing #7595769

Concept As at
2022-06-30
As at
2021-12-31
Consolidated balance sheet
Balance sheet
Assets
Non-current assets
Property, plant and equipment
Buildings, net
JPY
JPY
Property, plant and equipment
4,440,000 JPY
JPY
Investments and other assets
Investments in capital
100,000 JPY
100,000 JPY
Other
19,000 JPY
19,000 JPY
Investments and other assets
61,942,000 JPY
93,868,000 JPY
Long-term prepaid expenses
6,074,000 JPY
17,090,000 JPY
Non-current assets
66,383,000 JPY
93,868,000 JPY
Current assets
Cash and deposits
2,858,734,000 JPY
3,454,714,000 JPY
Accounts receivable - trade
30,450,000 JPY
352,148,000 JPY
Accounts receivable - other
82,137,000 JPY
4,179,000 JPY
Prepaid expenses
82,680,000 JPY
120,977,000 JPY
Supplies
2,970,000 JPY
3,222,000 JPY
Other
11,000 JPY
12,000 JPY
Current assets
3,438,448,000 JPY
4,198,008,000 JPY
Assets
3,504,831,000 JPY
4,291,876,000 JPY
Liabilities
Current liabilities
Short-term borrowings
241,666,000 JPY
238,880,000 JPY
Deposits received
7,462,000 JPY
6,320,000 JPY
Accounts payable - other
56,018,000 JPY
106,247,000 JPY
Income taxes payable
10,887,000 JPY
59,242,000 JPY
Lease liabilities
3,540,000 JPY
2,674,000 JPY
Accrued expenses
14,128,000 JPY
16,846,000 JPY
Current liabilities
467,761,000 JPY
430,211,000 JPY
Non-current liabilities
Long-term borrowings
283,324,000 JPY
255,544,000 JPY
Lease liabilities
8,559,000 JPY
6,372,000 JPY
Non-current liabilities
299,432,000 JPY
267,673,000 JPY
Liabilities
767,194,000 JPY
697,884,000 JPY
Liabilities and net assets
Shareholders' equity
2,729,957,000 JPY
3,586,312,000 JPY
Share capital
3,000,000,000 JPY
9,039,516,000 JPY
Capital surplus
586,425,000 JPY
9,063,645,000 JPY
Retained earnings
-856,325,000 JPY
-14,516,735,000 JPY
Treasury shares
-142,000 JPY
-113,000 JPY
Share acquisition rights
7,680,000 JPY
7,680,000 JPY
Net assets
2,737,637,000 JPY
3,593,992,000 JPY
Liabilities and net assets
3,504,831,000 JPY
4,291,876,000 JPY
Net assets
Shareholders' equity

Talk to a Data Expert

Have a question? We'll get back to you promptly.